))
Unlocking the potential of induced pluripotent stem cells
Manage episode 349788288 series 3291201
Content provided by CCRM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CCRM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring:
Dr. Lise Munsie, Vice President, iPSC Technology Platform, CCRM
Dr. Stephen Sullivan, Programme Manager, Global Alliance for iPSC Therapies (GAiT)
Drs. Lise Munsie and Stephen Sullivan explore some of the biggest challenges that will need to be addressed to unlock the potential of induced pluripotent stem cells (iPSCs), from regulatory issues to quality assurance and safety. Listen to hear about the proactive approach CCRM takes with its iPSC Excellence Team. You’ll also hear why having a central, international resource for organizations developing therapies from clinical-grade iPSCs is key for the cell and gene therapy industry, and how GAiT delivers this. This wide-ranging episode touches on the importance of contract development and manufacturing organizations (CDMOs) in bridging “professional silos;” global equity-of-access to these technologies as they move closer to the clinic; and the importance of diversity in clinical trials to ensure no patient group is left behind.
Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.
18 episodes
Share
